| JE-VAX® |
BIKEN |
Inact.-MB |
Nakayama Beijing-1 |
2 doses at 0 and 28 days; boost 3 yrs |
Worldwide |
≥ 1 yr |
JE-VAX is no longer manufactured; existing stocks expired in May 2011 |
| JEBIK V |
BIKEN |
Inact.-Culture |
Beijing-1 |
2 doses at 6–26 day interval; boost at 1 yr |
Japan |
≥ 6 months |
Currently suspended from pediatric vaccination schedule in Japan. |
| KD-287 |
Kaketsuken |
Inact.-Culture |
Beijing-1 |
3 dose regimen |
Japan |
≥ 6 months |
Also known as ENCEVAC®, JEIMMUGEN INJ |
| SA-14-14-2 |
Chengdu Institute |
Live-attenuated |
SA14-14-2 |
Single dose; boost at 9 mo. or 1 yr |
China, Nepal, Korea, India |
≥ 9 months |
Also known as CD.JEVAX® |
| IC51 |
Intercell AG |
Inact.-Culture |
SA14-14-2 |
2 doses at 0 and 28 days; boost 1 yr |
United States, Europe, Canada, Australia, Hong Kong and Switzerland |
≥ 17 yr |
Also known as IXIARO® and JESPECT®; longterm efficacy undetermined |
| JE-CV |
Saofi-Aventis |
Live-Chimeric |
SA14-14-2 |
N/A |
In Clinical trials |
N/A |
Also called IMOJEV or ChimeriVax™-JE; prM/E of JE-SA14-14-2 cloned into YFV-17D backbone; high seroconversion rate following 1 or 2 doses |
